CTEV logo

CLARITEV CORP

CTEVNYSE
πŸ† #2671 by market capEarnings Nov 5US Equity
$35.33β–² $0.37 (+1.06%)
Live
1hβ–Ό 0.4%
24hβ–² 1.1%
7dβ–² 35.9%
14dβ–² 48.4%
30dβ–² 18.4%
1yβ–Ό 46.7%
🏦Market Cap
$602M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+5.5%
Slowing
πŸ“ŠGross Margin
73.2%
High
πŸ’΅FCF Margin
7.5%
Moderate
βš–οΈP/S Ratio
0.6x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$34.94 – $35.87
52-Week Range
$11.50 – $74.07
Volume
$3.00B
Avg Volume
$3.84B
Shares Outstanding
17.1M
Next Earnings
Sep 12, 2026

Fundamentals Snapshot

Annual Revenue
$965M
Last Q Revenue
$257M
P/E Ratio
β€”
P/S Ratio
0.6x
EPS (TTM)
$-17.32
Dividend Yield
β€”

Why Investors Own CTEV

  • βœ“High-growth profile β€” revenue up +45.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 55% gross margin and 13% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$965Mβ–² +42.5% YoY
Gross Margin (TTM)
54.9%β–² +0.0% YoY
Operating Income (TTM)
$293Mβ–² +42.5% YoY
Free Cash Flow (TTM)
$127Mβ–² +42.5% YoY

About CLARITEV CORP

Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologiesβ€”including descriptive, predictive, and prescriptive analyticsβ€”to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Buy
12 analysts
Strong Buy4
Buy6
Hold2
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

BenzingaΒ·2d ago

Claritev Analysts Raise Their Forecasts Following Q2 Earnings

CTEV reported better-than-expected Q2 results and raised FY26 sales guidance. Analysts maintain Buy ratings with increased price targets.

πŸ›°οΈ
BenzingaΒ·2d ago

Citigroup Maintains Buy on Claritev, Raises Price Target to $45

Citigroup analyst Daniel Grosslight maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $40 to $45.

🌌
BenzingaΒ·2d ago

Canaccord Genuity Maintains Buy on Claritev, Raises Price Target to $43

Canaccord Genuity analyst Richard Close maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $37 to $43.

YahooΒ·4d ago

Claritev Q2 Earnings Call Highlights

Claritev (NYSE:CTEV) reported second-quarter revenue growth, record bookings and higher cash flow, prompting the healthcare technology company to raise its full-year revenue, adjusted EBITDA and free-cash-flow outlook. Revenue totaled $257.5 million in the second quarter, up 6.6% from a year earlie

SeekingAlphaΒ·4d ago

Claritev Corporation 2026 Q2 - Results - Earnings Call Presentation

2026-08-08. The following slide deck was published by Claritev Corporation in conjunction with their 2026 Q2 earnings call.

YahooΒ·4d ago

Claritev Corp (CTEV) (Q2 2026) Earnings Call Highlights: Record Bookings and AI-Driven Growth ...

Claritev Corp (CTEV) beats expectations with 6.6% revenue growth and record $74 million ACV bookings in the first half of 2026, driven by claims intelligence and AI initiatives.